Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

4 janvier 2018

12:15
Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, is pleased to announce that Gynecologic Oncology Associates/Women's Cancer Research Foundation (GOA/WCRF)...

11:33
Beckman Coulter Diagnostics today announced the addition of 6-Acetylmorphine (6-AM) and Buprenorphine (BUP) assays to its broad menu of drugs-of-abuse tests that meet the demands of onsite testing laboratories. Laboratories worldwide using Beckman...

11:30
Avelas Biosciences, Inc., a clinical stage oncology-focused company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced the completion of Period 1 patient enrollment in its...

11:19
Feinstein Institute for Medical Research Professor Haichao Wang, PhD, received a $1.2 million grant from the National Institutes of Health's (NIH) National Institute for General Medical Sciences (NIGMS) to continue his search to identify different...

10:47
A groundbreaking new study published in the Journal of Psychology of Sports and Exercise has found that swearing aloud can increase physical performance, strength, and power associated with exercise. According to the...

09:06
The German Center for Neurodegenerative Diseases (DZNE), ChemDiv and Torrey Pines Investment announced today the launch of a pre-commercial translational R&D program that will identify small molecule leads modulating NLRP3 inflammasome assembly and...

08:58
The rate of sexually transmitted virus-related mouth and throat cancer is rising 2.5 percent per year in the United States, even though the overall incidence of head and neck cancer is decreasing, according to a new study....

08:15
Bluefield Innovations, a collaboration between Deerfield Management and The Johns Hopkins University to catalyze early stage therapeutic development, announced today the acceptance and funding of its first project. The target, the enzyme RNA...

08:05
Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the acceptance of data from its...

08:05
Biocept, Inc. , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the issuance of Australian Patent No....

08:00
Eiger BioPharmaceuticals, Inc. , focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 ULTRA study.  ULTRA is a randomized, placebo-controlled study designed to...

08:00
Beacon Discovery, a leading drug discovery company focused on G-Protein Coupled Receptor (GPCR) research, today announced it has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the terms of the agreement,...

08:00
As Centerline Biomedical, Inc. prepares to meet with investors, strategic partners and companies in the healthcare industry during the JP Morgan Healthcare Conference, it successfully completed a fifth preclinical study at Cleveland Clinic facilities...

08:00
Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of a Phase 1b clinical trial of the company's novel immuno-oncology therapeutic candidate, LYC-55716, in...

08:00
BlueWind Medical, developer of a miniature wireless neurostimulation platform for the treatment of multiple clinical indications, announced today the publication of clinical results of OPTIMIST Study. The multi-center prospective study, tested...

08:00
Neuraltus Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases announced today the completion of the last patient visit in the confirmatory Phase 2 study of...

07:45
Cellect Biotechnology Ltd. , a developer of a novel stem cell selection technology, announced that it has successfully completed transplantation of the first group of three patients using Cellect's ApoGrafttm technology in the Company's Phase I/II...

07:30
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer's disease (AD), PMN310, showed absence...

07:30
Rigel Pharmaceuticals, Inc.  today announced that Raul Rodriguez, the company's president and chief executive officer, will present an update on its product pipeline and a financial overview at the upcoming 36th Annual J.P. Morgan Healthcare...

07:00
Conference call and webcast January 4, 2018 at 8:00am ESTWebcast may be accessed via the Investor and Media page of the Audentes websiteCall may be accessed by dialing 1-833-659-8620 and using conference ID#: 4957669 Audentes Therapeutics, Inc. , a...

06:13
RDD Pharma, a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders, announced today they have completed enrollment in the pivotal Phase 3...

05:25
Alligator Bioscience , a biotechnology company developing tumor-directed immunotherapies, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held 8-10 January, 2018 in San Francisco, US. Chief...

04:22
Cantargia AB ("Cantargia") has been notified that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's second, follow-up patent application in the solid tumours patent family, no. 15/196,795....

04:00
Hycor Biomedical, a leading manufacturer of in vitro diagnostic products for allergy and autoimmune testing, announced today that it has applied the CE mark to its allergy testing system, NOVEOStm, along with an initial menu of Total IgE and over one...

03:07
Les récepteurs couplés aux protéines G (RCPG) de classe B exercent une action essentielle dans l'homéostasie hormonale et sont des cibles thérapeutiques importantes pour une variété de maladie, y compris les troubles métaboliques tels que le diabète...

03:00
If approved, BAREMSIS would be the first antiemetic with an indication for:  - rescue treatment of PONV after failed prophylaxis, and  - combination prophylaxis of PONV with standard antiemetics  Acacia Pharma Group Ltd ("Acacia Pharma"), a...

03:00
Publication in Nature highlights opportunities to target C5a receptor with selective small molecules via novel mechanism of action   Sosei Group Corporation ("Sosei"); TSE Mothers Index:4565) announces that scientists at its wholly owned...

03:00
Aujourd'hui, Hycor Biomedical, un grand fabricant de produits de diagnostics in vitro pour les tests d'allergie et auto-immunes, a annoncé qu'elle avait demandé le marquage CE pour son système de test d'allergie NOVEOStm, avec un menu initial d'IgE...


3 janvier 2018

21:23
Class B G protein-coupled receptors (GPCRs) exert essential action in hormonal homeostasis and are important therapeutic targets for a variety of diseases including metabolic disorders such as type 2 diabetes. These receptors consist of an...

19:00
6-Month OPTIMIST Study show BlueWind Renovatm is a safe, minimally invasive system that offers significant improvements for Over Active Bladder patients.  BlueWind Medical, developer of a miniature wireless neurostimulation platform for the...

16:05
Momenta Pharmaceuticals, Inc. and Mylan N.V. today announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) injection. EYLEA is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for...

15:59
PharmaMar (MCE : PHM) a annoncé le lancement de la procédure de révision d'Aplidin® (plitidepsine) par l'Agence européenne des médicaments (AEM) pour le traitement du myélome réfractaire et récidivant.      (Logo:...

10:30
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, announced today positive results from the Phase 2a clinical trial of Ovarest®, an oral formulation of leuprolide,...

10:10
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced the three-year outcomes data from the Rez?m II pivotal clinical trial of...

09:00
Undiagnosed sleep apnea is highly prevalent among hospital patients, and treating it after they're discharged can improve their chances of long-term survival, according to a ResMed-funded study published in the American Journal of Medicine....

08:00
Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion PillTM platform technology, today announced that the Canadian Intellectual Property Office has issued a Certificate of...

08:00
OncoSec Medical Incorporated ("OncoSec" or the "Company") , a company developing intratumoral cancer immunotherapies, announced its anticipated operational milestones for 2018 and a review of business highlights for year-end 2017. "The momentum we...

07:42
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health (MoH) for its...

07:36
PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma.      (Logo:...

07:30
Palatin Technologies, Inc. , a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the U.S. Food and...

07:00
Article in JACC: Basic to Translational Science Validates Feasibility and Unique Potential of LBS to Detect Biomarkers for Coronary Artery Disease  PLAQUETEC LTD ("PlaqueTec") today announced the publication of the first peer-reviewed article...

06:30
Ardelyx, Inc. today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program, designed to support the registration of tenapanor for the treatment of patients with irritable bowel syndrome with...

03:00
Article in JACC: Basic to Translational Science Validates Feasibility and Unique Potential of LBS to Detect Biomarkers for Coronary Artery Disease  PLAQUETEC LTD ('PlaqueTec') today announced the publication of the first peer-reviewed article...


2 janvier 2018

12:30
A first-of-its-kind study published in the Pain Management issue of AACC's The Journal of Applied Laboratory Medicine shows that a new drug testing approach dramatically improves detection of illicit benzodiazepine use. This could help to curb abuse...

12:30
Innovative research published in the Obesity issue of AACC's journal, Clinical Chemistry, demonstrates that people are at greater risk for obesity if they produce higher than normal levels of insulin after eating processed carbohydrates. These...

12:30
A special issue of AACC's The Journal of Applied Laboratory Medicine, "Laboratory Support of Pain Management," features groundbreaking new drug tests that could reverse the staggering climb of prescription drug overdoses in the U.S....

11:36
Zyga Technology, Inc., a medical device company focused on the design, development and commercialization of minimally invasive devices to treat underserved conditions of the lumbar spine, today announced publication of clinical outcomes for the first...

09:00
BiondVax Pharmaceuticals Ltd. , developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its key patents titled "A Synthetic or Recombinant Influenza Multi-Epitope...

07:52
Bone Index Ltd., one of Europe's top new manufacturers of medical devices, announces that the American Medical Association (AMA) has issued a new Category III CPT® code* for Bindex® measurement to help physicians in diagnosing osteoporosis. "In...

07:00
Compugen Ltd. , a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced upcoming poster and oral presentations on COM701, a first-in-class therapeutic antibody candidate targeting...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19